Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in liver and respiratory rare disease therapeutics and infectious disease vaccines, has announced its participation in four upcoming investor conferences in September 2025.
The company will participate in fireside chats at Citi's Biopharma Back to School Conference (Sept 2), Wells Fargo Healthcare Conference (Sept 3), and Cantor Global Healthcare Conference (Sept 5). Additionally, Arcturus will deliver a presentation at the H.C. Wainwright Global Investment Conference (Sept 9).
Arcturus Therapeutics (NASDAQ:ARCT) reported Q2 2025 financial results and pipeline updates. Key highlights include: Q2 revenue of $28.3M (down from $49.9M in Q2 2024) and net loss of $9.2M ($0.34 per share). The company maintains a strong cash position of $253.4M, extending runway into 2028.
Pipeline progress includes: Cystic fibrosis (ARCT-032) Phase 2 interim data from nine participants expected September 2025; OTC deficiency (ARCT-810) showed positive Phase 2 results with Phase 3 planning in H1 2026; KOSTAIVE® regulatory submissions advancing globally; and Seasonal flu vaccine (ARCT-2138) demonstrated positive Phase 1 results in both young and older adults.
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has scheduled its second quarter 2025 financial results announcement. The company will release its Q2 results on Monday, August 11, 2025, after market close.
A conference call and webcast will follow at 4:30 PM Eastern Time the same day. Investors can access the call via domestic (1-800-274-8461) or international (1-203-518-9814) numbers using the conference ID "ARCTURUS".
Arcturus Therapeutics (NASDAQ:ARCT), a commercial mRNA medicines company specializing in infectious disease vaccines and rare diseases, has announced its participation in two upcoming investor conferences.
The company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on July 29, 2025, at 12:40 p.m. ET, and deliver a presentation at the CG 45th Annual Growth Conference on August 12, 2025, at 8:30 a.m. ET.
Summary not available.
Arcturus Therapeutics (Nasdaq: ARCT), a commercial mRNA medicine company specializing in infectious disease vaccines and liver and respiratory rare diseases, has announced its participation in two upcoming investor conferences in June 2025:
- Jefferies Global Healthcare Conference: Presentation scheduled for Wednesday, June 4, 2025, at 4:20 p.m. ET
- Goldman Sachs Annual Global Healthcare Conference: Fireside Chat scheduled for Monday, June 9, 2025, at 3:20 p.m. ET
Arcturus Therapeutics (Nasdaq: ARCT), a commercial messenger RNA medicines company specializing in infectious disease vaccines and liver and respiratory rare diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its financial results for the quarter ended March 31, 2025, after market close on Monday, May 12, 2025.
A conference call and webcast will follow at 4:30 PM Eastern Time on the same day. Investors can access the call through domestic (1-800-267-6316) or international (1-203-518-9783) lines using the Conference ID: ARCTURUS.
Arcturus Therapeutics (Nasdaq: ARCT) has received Fast Track Designation from the U.S. FDA for its self-amplifying mRNA vaccine candidate ARCT-2304, targeting pandemic influenza A virus H5N1. The designation, granted for vaccines addressing serious conditions, will expedite the development and review process through enhanced FDA communication, priority review eligibility, and potential rolling review.
The Phase 1 clinical study for ARCT-2304 commenced in November 2024. The vaccine utilizes Arcturus' proprietary STARR® technology platform for next-generation mRNA vaccines. The project is fully supported by federal funds from the Department of Health and Human Services, specifically through BARDA under contract number 75A50122C0007.